Uptake of IUdR in Malignant Tumors
Author Information
Author(s): P.A. Philip, K.D. Bagshawe, F. Searle, A.J. Green, R.H.J. Begent, E.S. Newlands, G.J.S. Rustin, T. Adam
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Can the selective uptake of IUdR in neoplastic cells be enhanced by pre-treatment with hydroxyurea?
Conclusion
A significant proportion of human tumors show detectable uptake of 131-IUdR, suggesting potential for targeted therapy.
Supporting Evidence
- 50% of patients showed evidence of uptake by at least one disease site.
- Significant uptake was noted in the spine and stomach.
- Three out of four brain lesions showed marked uptake of radioactivity.
Takeaway
This study looked at how a special drug can be seen in cancer cells, helping doctors find and treat tumors better.
Methodology
Patients were pre-treated with hydroxyurea before receiving 131-IUdR, and imaging was performed to assess uptake.
Limitations
Some tumors may have been missed due to suppressed DNA synthesis from hydroxyurea treatment.
Participant Demographics
Mean age 51.6 years, 16 males and 10 females.
Want to read the original?
Access the complete publication on the publisher's website